Keymed Biosciences Balance Sheet Health
Financial Health criteria checks 4/6
Keymed Biosciences has a total shareholder equity of CN¥3.0B and total debt of CN¥436.9M, which brings its debt-to-equity ratio to 14.6%. Its total assets and total liabilities are CN¥3.9B and CN¥896.1M respectively.
Key information
14.6%
Debt to equity ratio
CN¥436.87m
Debt
Interest coverage ratio | n/a |
Cash | CN¥2.72b |
Equity | CN¥2.99b |
Total liabilities | CN¥896.11m |
Total assets | CN¥3.88b |
Recent financial health updates
Recent updates
There's Reason For Concern Over Keymed Biosciences Inc.'s (HKG:2162) Massive 28% Price Jump
May 13News Flash: 10 Analysts Think Keymed Biosciences Inc. (HKG:2162) Earnings Are Under Threat
Apr 03Keymed Biosciences Inc. (HKG:2162) Just Reported And Analysts Have Been Cutting Their Estimates
Mar 31A Look At The Intrinsic Value Of Keymed Biosciences Inc. (HKG:2162)
Nov 13Analysts Just Made A Noticeable Upgrade To Their Keymed Biosciences Inc. (HKG:2162) Forecasts
Sep 03Broker Revenue Forecasts For Keymed Biosciences Inc. (HKG:2162) Are Surging Higher
Mar 21Companies Like Keymed Biosciences (HKG:2162) Are In A Position To Invest In Growth
Jun 27Financial Position Analysis
Short Term Liabilities: 2162's short term assets (CN¥2.9B) exceed its short term liabilities (CN¥314.2M).
Long Term Liabilities: 2162's short term assets (CN¥2.9B) exceed its long term liabilities (CN¥581.9M).
Debt to Equity History and Analysis
Debt Level: 2162 has more cash than its total debt.
Reducing Debt: Insufficient data to determine if 2162's debt to equity ratio has reduced over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: 2162 has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if 2162 has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.